Harlequin Syndrome as a Complication of Epidural Anesthesia

2014 ◽  
Vol 34 (3) ◽  
pp. 57-61 ◽  
Author(s):  
Bryan Boling ◽  
Christopher Key ◽  
Justin Wainscott ◽  
Annette Rebel

Harlequin syndrome is a rare neurological condition that results in unilateral facial flushing and sweating. Although the syndrome is generally a benign condition with complete resolution if appropriate treatment is initiated, unilateral facial flushing can be a sign of several serious conditions and should be thoroughly investigated. Sudden onset of facial flushing related to harlequin syndrome developed in a patient who had bilateral lung transplant with postoperative epidural anesthesia for pain control. Differential diagnosis includes neurovascular disease (acute stroke), malignant neoplasm of brain or lung, Horner syndrome, idiopathic hyperhidrosis, and Frey syndrome. Harlequin syndrome is often easily treated by discontinuing the anesthetic or adjusting placement of the epidural catheter. (Critical Care Nurse. 2014;34[3]:57–61)

Neurology ◽  
2018 ◽  
Vol 91 (6) ◽  
pp. 278-281
Author(s):  
Jennifer H. Kang ◽  
Muhammad Shahzad Zafar ◽  
Klaus-Georg E. Werner

Congenital harlequin syndrome is rare dysautonomia of the face most often reported in adults and rarely in infants and children. It is a diagnosis of exclusion and a seemingly benign condition. We report a case of a 6-month-old girl with episodic unilateral and bilateral facial flushing provoked upon awakening and resolved with sleeping with associated autonomic features consistent with harlequin syndrome. This is followed by a review of cases identified regarding this condition in infants and children.


2021 ◽  
Vol 36 (1) ◽  
pp. 34-41
Author(s):  
Lia Argevani ◽  
Michael J. Schuh ◽  
Sheena Crosby

Objective: To report pharmacogenomics post-related bradykinesia secondary to phenoconversion in an elderly post-bilateral lung transplant patient. Summary: The patient was a 68-year-old double lung transplant patient taking the immunosuppressant and CYP3A4/5 substrate tacrolimus concomitantly with 2 CYP3A4/5 inhibitor medications, fluconazole and diltiazem. This drug combination post-dosing resulted in debilitating bradykinesia 1-2 hours after dosing, increasing the risk of falls and possible increased mortality and morbidity risk. Conclusion: Taking tacrolimus in combination with CYP3A4/5 inhibitors may increase neurologic adverse effects resulting in increased fall and associated increased mortality and morbidity risk.


2019 ◽  
Vol 23 ◽  
pp. 77-80 ◽  
Author(s):  
Laila S. Al Yazidi ◽  
Julie Huynh ◽  
Philip N. Britton ◽  
C. Orla Morrissey ◽  
Tony Lai ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document